Locations:
Search IconSearch
April 5, 2022/Cancer

Total Neoadjuvant Therapy Followed by Endoluminal Submucosal Dissection for Colorectal Cancer: A Case Report

Case highlights potential benefits of this staged, dual-therapy approach

22-DDI-2684108 ESD after TNT DIAGNOSIS Hero 650×450

History and presentation

A 41-year-old woman who had experienced four months of rectal bleeding was referred to Cleveland Clinic and Emre Gorgun, MD, Section Chief of Colorectal Surgical Oncology, after a diagnostic colonoscopy identified a potentially malignant rectal mass. Flexible endoscopy inspection and biopsy confirmed a diagnosis of rectal adenocarcinoma. Clinical staging classified the cancer as stage IIA (T3N0).

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

After the patient completed chemoradiation in May 2020, a restaging MRI scan revealed a moderate response. Cleveland Clinic’s Colorectal Cancer Multidisciplinary Tumor Board recommended that the patient undergo total neoadjuvant therapy (TNT).

Historically, chemoradiation followed by total mesorectal excision and adjuvant chemotherapy has been the standard of care for locally advanced rectal cancer.

TNT is a relatively new organ-sparing and distant micrometastases-prevention protocol from the Organ Preservation in Rectal Adenocarcinoma trial in which patients diagnosed with stage II or III locally advanced rectal cancer receive upfront chemoradiotherapy and consolidation chemotherapy. Patients who achieve a complete response on multimodal assessment following TNT are placed on active surveillance, which involves physical exam, flexible sigmoidoscopy, monitoring of carcinoembryonic antigen levels and MRI and CAT scans at regular intervals for at least five years. About 30 percent of patients can avoid surgery with this approach.

Treatment and follow-up

The patient completed TNT chemotherapy in November 2020 and showed a complete response. The following month, she entered the watch-and-wait protocol.

During a subsequent surveillance flexible scope evaluation, clinicians detected polyp regrowth. Pathology revealed a rectal scar and some residual adenoma with low-grade dysplasia.

The patient underwent endoscopic submucosal dissection (ESD) of her rectal scar lesion in October 2021. Recent advances in equipment and techniques have made it possible to endoscopically remove precancerous, cancerous and complex polypoid lesions that traditionally required surgical resection, using ESD or other endoluminal approaches.

Advertisement

Pathology following ESD showed the patient’s dissection margins were negative for dysplasia. The tumor board recommended that she continue on the watch-and-wait protocol.

Her most recent follow-up scans confirmed no evidence of cancer recurrence.

“She remains disease-free and the site that we treated with advanced endoscopy is perfectly healed, with nice epithelialization,” says Dr. Gorgun, who is also Director for Lower GI of Cleveland Clinic’s Endoluminal Surgery Center.

Were it not for this multimodal TNT/ESD option, the patient might have required major surgery to remove her rectum, leaving her with a permanent ostomy, Dr. Gorgun explains. This combined approach “gave us the extra comfort that we can monitor this patient further without her undergoing a major operation.”

<p>Endoscopy at the time of diagnosis shows the rectal adenocarcinoma.</p>

<p>After total neoadjuvant therapy.</p>

<p>After endoscopic submucosal dissection.</p>

<p>Pathology following TNT and ESD.</p>

Slide 1/4

Not one, but two innovative approaches

Combining TNT with ESD is relatively new and the option is not widely available. Cleveland Clinic was one of the first centers in the United States to incorporate TNT into standardized care paths and to pioneer the dual TNT/ESD strategy. Its use is not based on an individual surgeon’s decision, but rather on expert consensus. The tumor board discusses evidence-based information to support an individualized treatment plan for each patient.

Cleveland Clinic offers TNT to clinically appropriate colorectal cancer patients. Treatment takes approximately six months, and up to 50% of patients have a complete response.

Advertisement

For patients with evidence of residual cancer, abnormal tissue or high-grade dysplasia after TNT, ESD is a potential next step to remove remaining complex polyps or lesions detected during surveillance. Adding ESD to a patient’s treatment plan maintains an organ-sparing strategy.

ESD has been used for other cancer patients, such as those with early esophageal and gastric cancers. Dr. Gorgun and colleagues adapted the technique to colorectal cancer management.

Although difficult to directly compare with traditional major surgery outcomes, in general TNT and ESD patients have minimal side effects or complications, he says. “So it’s certainly much more beneficial.”

“This is a cutting-edge, innovative, and futuristic approach,” Dr. Gorgun says.

He and his colleagues plan to explore ways to optimize the safety and effectiveness of this combination treatment strategy going forward.

Advertisement

Related Articles

Cancer patient being hugged by a loved one
September 4, 2024/Cancer/Blood Cancers
Study Finds Immunotherapy Increases Three-Year Survival in Adults with B-Cell Precursor Acute Lymphoblastic Leukemia

Blinatumomab plus chemotherapy improves overall survival and relapse-free survival over chemotherapy alone

Doctor and team talking to patient in hospital bed
August 30, 2024/Cancer/Patient Support
New Cellular and Immunotherapy Service Provides Patients with Standard of Care and Clinical Trial Opportunities for Novel Therapies

Patients receive specialized inpatient and outpatient care for cellular, gene and immune cell-engaging therapies

Before and after scan
August 28, 2024/Cancer/Research
Case Study: Patient with Metastatic Urothelial Carcinoma Has No Remaining Evidence of Disease

Treatment involved checkpoint inhibitor, surgery and intravesical therapy

Dr. Maciejewski
August 23, 2024/Cancer/Research
Studies Evaluate Anti-Complement Inhibitors for Treating Paroxysmal Nocturnal Hemoglobinuria

Researchers Assess Real-Life Experiences of Patients Treated Outside of Clinical Trials

Dr. Raza
August 19, 2024/Cancer/Research
Understanding the Role of Palliative Care in AL Amyloidosis

Multi-specialty coordination essential for improving quality of life

Dr. Chirag Shah and colleague
August 12, 2024/Cancer/Research
DCISionRT Decision Score Predicts the Need of Radiation Therapy for Treating Ductal Carcinoma in Situ

Seven-gene biosignature becomes first effective means to reduce over- and under-treatment with radiation therapy

Diffuse large B-cell lymphoma
August 1, 2024/Cancer/Research
Emerging Second- and Third-Line Treatments Improve Outcomes in Diffuse Large B-Cell Lymphoma

CAR T-cell therapy, bispecifics and antibody drug conjugates have changed disease management

Ad